An independent two-stage DCF analysis by a frontier AI model.
AMETEK represents a masterclass in industrial compounding. The company operates entirely outside the spotlight, manufacturing the highly specialized, boring, yet mission-critical instruments and electromechanical devices that power modern industry. By targeting fragmented niche markets, AME avoids direct competition with massive conglomerates and establishes deep, sticky relationships with its customers based on precision and reliability, not price.
This strategy creates an immensely powerful cash generation engine. AME relentlessly extracts operational efficiencies from its existing businesses to fund a continuous pipeline of highly accretive, bolt-on acquisitions. However, the market has fully recognized the brilliance of this model. Trading at a premium multiple, the margin of safety is currently negative. It is an exceptional company trading at a price that leaves little room for execution missteps or a broader industrial slowdown.
An 8.0% free cash flow growth rate reflects AME's proven ability to expand organically at a modest pace while continually layering on margin-accretive, bolt-on acquisitions. This dual-engine approach, combined with relentless operational efficiency, drives highly predictable compounding.
An 8.0% discount rate is utilized. AME's massive diversification across hundreds of niche end markets (aerospace, medical, automation) significantly insulates it from isolated economic shocks, lowering its overall equity risk profile compared to a cyclical industrial.
A 3.0% terminal growth rate assumes AME will grow slightly faster than long-term GDP, propelled by structural mega-trends like global industrial automation, precision manufacturing, and the increasing complexity of medical devices.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $223.13 | $178.50 | $148.75 | $127.50 | $111.56 |
| 2.5% | $255.00 | $198.33 | $162.27 | $137.31 | $119.00 |
| 3.0% | $297.50 | $223.12 | $178.50 | $148.75 | $127.50 |
| 3.5% | $357.00 | $255.00 | $198.33 | $162.27 | $137.31 |
| 4.0% | $446.25 | $297.50 | $223.13 | $178.50 | $148.75 |
■ Undervalued vs current price ■ Overvalued vs current price
This rate explicitly models AME's historic 'Growth Playbook,' combining low single-digit organic growth driven by pricing power and innovation with a consistent cadence of highly accretive M&A funded by its massive free cash flow generation.
While not immune to a severe global industrial downturn, AME is far less cyclical than traditional manufacturers. Its extreme diversification across end markets (medical, aerospace, food/beverage) and its focus on critical, non-discretionary instruments buffer its earnings significantly.
AMETEK is a phenomenal business, but its compounding strategy is widely recognized and priced into the stock. The current valuation demands near-flawless execution of its M&A strategy and assumes a benign macroeconomic environment, compressing the margin of safety.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.